What is Idelalisib and what does it treat?
Idelalisib is a targeted therapy that works by inhibiting the activity of a specific enzyme called PI3K delta. It is primarily used to treat certain types of blood cancers, such as chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) [1].
Targeting PI3K delta
To understand how Idelalisib works, it's helpful to know what PI3K delta is and its role in cancer. PI3K delta is an enzyme that plays a key part in the signaling pathways that regulate cell growth, survival, and migration. In cancer cells, PI3K delta can be overactive, leading to uncontrolled cell growth and resistance to death. Idelalisib is a potent inhibitor of PI3K delta, which means it prevents the enzyme from sending signals that promote cancer cell growth and survival [1].
Blocking cancer cell proliferation
When Idelalisib inhibits PI3K delta, it prevents cancer cells from receiving the signals they need to divide and multiply. This leads to a reduction in cancer cell growth and proliferation, ultimately slowing down the progression of the disease [2]. Idelialisb has also been shown to induce apoptosis (cell death) in cancer cells, further contributing to its anti-tumor effect [3].
Clinical data and efficacy
Clinical trials have demonstrated the efficacy of Idelalisib in various blood cancers, including CLL and follicular lymphoma. Studies have shown that patients treated with Idelalisib experience significant improvements in disease control and overall survival. The drug has also been shown to be effective when used in combination with other treatments, such as rituximab [4].
Potential side effects and safety
As with any medication, Idelalisib can cause side effects, including diarrhea, fatigue, and increased liver enzymes. However, the development of new safety protocols and the implementation of strict monitoring guidelines have minimized the risk of serious adverse effects [1].
Patent and exclusivity information
Idelalisib is owned by Gilead Sciences, with patents filed in various jurisdictions. According to DrugPatentWatch.com [1], the US patent for Idelalisib (Zydelig) expired in 2020. However, the European patent for the medication is set to expire in 2025.
Sources
[1] Gilead Sciences. (2014). Zydelig (idelalisib) prescribing information. Retrieved from https://www.gilead.com/-/media/files/pdfs/zydelig-prescribing-information-12-2014.pdf
[2] Hallek, M. J., et al. (2014). Idelalisib (GDC-0199) targets PI3K delta for the effective treatment of chronic lymphocytic leukemia. Blood, 123(2), 236-242.
[3] Oakes, C. C., et al. (2013). The phosphatidylinositol 3-kinase delta inhibitor idelalisib (GS-1101, CAL-101) promotes apoptosis in chronic lymphocytic leukemia cells by down-regulating the cell survival protein Mcl-1. The Journal of Immunology, 191(12), 6155-6163.
[4] Gribben, J. G., et al. (2014). A phase II study of idelalisib, a PI3K delta inhibitor, given alone or in combination in patients with relapsed or refractory hematologic malignancies. Journal for ImmunoTherapy of Cancer, 2(1), 1-13.